FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3016731125> ?p ?o ?g. }

• W3016731125 endingPage "113324" @default.
• W3016731125 startingPage "113324" @default.
• W3016731125 abstract "Neonatal hypoxic-ischemic encephalopathy remains the most important neurological problem of the newborn. Delays in diagnosing perinatal brain injuries are common, preventing access to acute therapies. Therefore, there is a critical need for therapeutic strategies that are beneficial when delivered beyond 24 h after birth. Here we show that Leukemia Inhibitory Factor (LIF) functions as an essential injury-induced neurotrophic cytokine in the CNS and that non-invasively administering LIF as late as 3 days after a hypoxic-ischemic insult improves neurological function. Using a mouse model of late preterm brain injury we show that astroglial and microglial/macrophage reactivity to hypoxia-ischemia was diminished at 3 days of recovery, but then exacerbated at 2 weeks of recovery in LIF haplodeficient mice. There also were significantly more CD68+/Iba-1+ cells in the ipsilateral striatum in LIF-Het mice compared to WT mice at 2 weeks of recovery. This desynchronized glial response was accompanied by increased neuronal cell death in the striatum and neocortex (Fluorojade C), hypomyelination (reduced MBP staining and thinner external capsule), increased extent of brain damage (Nissl) and diminished neurological function on sensorimotor tests. To our surprise, injured LIF-Het mice had ~7-fold higher IGF-1 levels than injured WT mice at 3 days after HI injury. Intranasally administered LIF activated the Jak-Stat-3 pathway both within the subventricular zone and the neocortex at 30 min after administration. When delivered with a delay of 3 days after the insult, intranasal LIF reduced the extent of brain injury by ~60%, attenuated astrogliosis and microgliosis in striatum, improved subcortical white matter thickness, increased numbers of Olig2+ cells in corpus callosum and improved performance on sensorimotor tests at 2 weeks of recovery. These studies provide key pre-clinical data recommending LIF administration as a neuroprotectant and regenerative cytokine and they highlight the feasibility of pursuing new therapeutics targeting the tertiary phase of neurodegeneration for hypoxic-ischemic encephalopathies." @default.
• W3016731125 created "2020-04-24" @default.
• W3016731125 creator A5040957024 @default.
• W3016731125 creator A5052001271 @default.
• W3016731125 creator A5063033933 @default.
• W3016731125 creator A5077444446 @default.
• W3016731125 creator A5087984965 @default.
• W3016731125 date "2020-08-01" @default.
• W3016731125 modified "2023-09-23" @default.
• W3016731125 title "Neuroregenerative and protective functions of Leukemia Inhibitory Factor in perinatal hypoxic-ischemic brain injury" @default.
• W3016731125 cites W1817224745 @default.
• W3016731125 cites W1913996147 @default.
• W3016731125 cites W1976273488 @default.
• W3016731125 cites W1980790915 @default.
• W3016731125 cites W1991165067 @default.
• W3016731125 cites W1995559307 @default.
• W3016731125 cites W2001500938 @default.
• W3016731125 cites W2004198397 @default.
• W3016731125 cites W2008791554 @default.
• W3016731125 cites W2011792758 @default.
• W3016731125 cites W2016560577 @default.
• W3016731125 cites W2017217471 @default.
• W3016731125 cites W2020591797 @default.
• W3016731125 cites W2023942293 @default.
• W3016731125 cites W2026282644 @default.
• W3016731125 cites W2026286443 @default.
• W3016731125 cites W2031147341 @default.
• W3016731125 cites W2034741420 @default.
• W3016731125 cites W2035657052 @default.
• W3016731125 cites W2037752270 @default.
• W3016731125 cites W2038293269 @default.
• W3016731125 cites W2039476938 @default.
• W3016731125 cites W2042016363 @default.
• W3016731125 cites W2043776713 @default.
• W3016731125 cites W2064074087 @default.
• W3016731125 cites W2067121396 @default.
• W3016731125 cites W2070091886 @default.
• W3016731125 cites W2071318158 @default.
• W3016731125 cites W2073074457 @default.
• W3016731125 cites W2091926606 @default.
• W3016731125 cites W2094617144 @default.
• W3016731125 cites W2102089787 @default.
• W3016731125 cites W2107661847 @default.
• W3016731125 cites W2111345918 @default.
• W3016731125 cites W2119409468 @default.
• W3016731125 cites W2147492811 @default.
• W3016731125 cites W2153284686 @default.
• W3016731125 cites W2153446990 @default.
• W3016731125 cites W2162696517 @default.
• W3016731125 cites W2163437443 @default.
• W3016731125 cites W2228229648 @default.
• W3016731125 cites W2267370441 @default.
• W3016731125 cites W2298291440 @default.
• W3016731125 cites W2472915223 @default.
• W3016731125 cites W2557589914 @default.
• W3016731125 cites W2558488237 @default.
• W3016731125 cites W2702783320 @default.
• W3016731125 cites W2791043077 @default.
• W3016731125 cites W2794350237 @default.
• W3016731125 cites W2799697733 @default.
• W3016731125 cites W2889719632 @default.
• W3016731125 cites W2898783666 @default.
• W3016731125 cites W2908416553 @default.
• W3016731125 cites W2916392902 @default.
• W3016731125 cites W2942602060 @default.
• W3016731125 cites W2954107975 @default.
• W3016731125 doi "https://doi.org/10.1016/j.expneurol.2020.113324" @default.
• W3016731125 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7304440" @default.
• W3016731125 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32320698" @default.
• W3016731125 hasPublicationYear "2020" @default.
• W3016731125 type Work @default.
• W3016731125 sameAs 3016731125 @default.
• W3016731125 citedByCount "15" @default.
• W3016731125 countsByYear W30167311252020 @default.
• W3016731125 countsByYear W30167311252021 @default.
• W3016731125 countsByYear W30167311252022 @default.
• W3016731125 countsByYear W30167311252023 @default.
• W3016731125 crossrefType "journal-article" @default.
• W3016731125 hasAuthorship W3016731125A5040957024 @default.
• W3016731125 hasAuthorship W3016731125A5052001271 @default.
• W3016731125 hasAuthorship W3016731125A5063033933 @default.
• W3016731125 hasAuthorship W3016731125A5077444446 @default.
• W3016731125 hasAuthorship W3016731125A5087984965 @default.
• W3016731125 hasBestOaLocation W30167311252 @default.
• W3016731125 hasConcept C11988809 @default.
• W3016731125 hasConcept C126322002 @default.
• W3016731125 hasConcept C142724271 @default.
• W3016731125 hasConcept C160539049 @default.
• W3016731125 hasConcept C170493617 @default.
• W3016731125 hasConcept C185856081 @default.
• W3016731125 hasConcept C203014093 @default.
• W3016731125 hasConcept C204232928 @default.
• W3016731125 hasConcept C25498285 @default.
• W3016731125 hasConcept C27284151 @default.
• W3016731125 hasConcept C2776914184 @default.
• W3016731125 hasConcept C2777209535 @default.
• W3016731125 hasConcept C2778690821 @default.
• W3016731125 hasConcept C2779830541 @default.

• next